Catalyst Pharmaceuticals Shares up 2.1% After US FDA Approves Increased Maximum Daily Dose of Co's Neuromuscular Disorder Drug
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.